AIP
TRVI icon

Ameritas Investment Partners’s Trevi Therapeutics TRVI Stock Holding History

Ameritas Investment Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Buy
9,727
+2,095
+27% +$30.5K ﹤0.01% 1452
2026
Q1 		$91K Hold
7,632
– – ﹤0.01% 1744
2025
Q4 		$95.6K Hold
7,632
– – ﹤0.01% 1732
2025
Q3 		$69.8K Buy
7,632
+1,300
+21% +$9.75K ﹤0.01% 1905
2025
Q2 		$34.6K Hold
6,332
– – ﹤0.01% 2401
2025
Q1 		$39.8K Hold
6,332
– – ﹤0.01% 2240
2024
Q4 		$26.1K Buy
6,332
+2,894
+84% +$9.26K ﹤0.01% 2518
2024
Q3 		$11.5K Hold
3,438
– – ﹤0.01% 2877
2024
Q2 		$10.2K Hold
3,438
– – ﹤0.01% 2921
2024
Q1 		$11.9K Hold
3,438
– – ﹤0.01% 2771
2023
Q4 		$4.61K Hold
3,438
– – ﹤0.01% 2980
2023
Q3 		$7.5K Hold
3,438
– – ﹤0.01% 2912
2023
Q2 		$8.22K Buy
+3,438
New +$8.66K ﹤0.01% 2957

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Ameritas Investment Partners's TRVI Position: Q2 2026 in Review

Ameritas Investment Partners increased its Trevi Therapeutics (TRVI) stake by 27% in Q2 2026, buying an estimated $30.5K and bringing the position to 9,727 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

Ameritas Investment Partners first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Ameritas Investment Partners held 9,727 shares of Trevi Therapeutics worth $181K as of Q2 2026.
  • Ameritas Investment Partners bought 2,095 Trevi Therapeutics shares in Q2 2026, an estimated $30.5K.
  • Trevi Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1452 holding.
  • Ameritas Investment Partners first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.